Can-Jun Ruan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Can-Jun Ruan has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Jose de Leon
Mental Health Research Center, Eastern State Hospital, Lexington, KY
25 shared publications - Carlos De Las Cuevas
University of La Laguna
15 shared publications - Georgios Schoretsanitis
Department of Psychiatry, Lausanne University Hospital and University of Lausanne, CH-1008 Prilly Lausanne, Switzerland; Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Lausanne University Hospital and University of Lausanne, CH-1005 Lausanne, Switzerland; The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY 11004, USA; Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY 11549, USA
15 shared publications - Emilio J. Sanz
Department of Physical Medicine and Pharmacology, School of Medicine, Universidad de La Laguna, Canary Islands, Spain
10 shared publications - Christoph U. Correll
Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
7 shared publications - Christopher Rohde
Department of Clinical Medicine, Aarhus University
7 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Juan José López-Ibor Foundation in Actas Españolas de Psiquiatría
- Vol. 54 (5) , 1-7
Informing Your Future Clozapine Patients of the Mortality Risk: Fear of Agranulocytosis vs. Pharmacovigilance Fatal Outcomes
- 15 October 2026
- Published by Juan José López-Ibor Foundation in Actas Españolas de Psiquiatría
- Vol. 54 (5) , 1-7
Open AccessInforming Your Future Clozapine Patients of the Mortality Risk: Fear of Agranulocytosis vs. Pharmacovigilance Fatal Outcomes
- Top Cited Papers
- 20 February 2026
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 34 (4) , 591-601
A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase
- 20 February 2026
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 34 (4) , 591-601
Top Cited PapersA Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase
- Open Access
- 12 December 2024
- Published by Wiley
Interindividual Variability in Olanzapine Steady-State Concentrations in Chinese: Exploring Single Nucleotide Polymorphisms of Metabolic Enzymes
Aims: Olanzapine, a second-generation antipsychotic, can cause dose-adverse drug reactions. Its steady-state concentration can vary due to several factors. This study explores how physiological factors, smoking, inflammation, concomitant medications, and metabolic enzyme single nucleotide polymorphisms (SNPs) influence its metabolic levels, aiming to guide personalized dosing. Methods: This study analyzed data from 310 olanzapine-treated patients at Beijing Anding Hospital. Liquid chromatography-mass spectrometry (LC-MS/MS) quantified 1002 serum concentrations. Eleven SNPs from CYP1A2, CYP3A5, UGT1A4, and FMO1/3 were identified through real-time fluorescence quantitative polymerase chain reaction (q-PCR). A Bayesian network was applied to elucidate causal relationships between variables, followed by g-computation to quantify the effect of individual factors on the dose-adjusted concentration (C/D ratio) of olanzapine. The Wilcoxon signed-rank test assessed the intra-individual variations in the steady-state C/D ratio. Results: The Bayesian network suggested causality between smoking, sex, sertraline, Danggui-Longhui, valproic acid, and the olanzapine C/D ratio. None of the SNPs reached significance levels. The Wilcoxon signed-rank test confirmed that both polypharmacy and inflammation increased the C/D ratio within individuals. G-computation showed that the log ratio of olanzapine C/D decreased by 0.392 ± 0.037 in males and 0.004 ± 0.001 with smoking. Danggui-Longhui, sertraline, and valproic acid reduced the ratio by 0.652 ± 0.131, 0.398 ± 0.127, and 0.328 ± 0.039, respectively. Conclusion: Our study confirms that sex, age, smoking, inflammation, and co-prescription with sertraline, Danggui-Longhui, and valproic acid contributed to variability in olanzapine’s steady-state concentration. Considering these factors in clinical practice may help to personalize olanzapine treatment in Asian patients.
- 12 December 2024
- Published by Wiley
Open AccessInterindividual Variability in Olanzapine Steady-State Concentrations in Chinese: Exploring Single Nucleotide Polymorphisms of Metabolic Enzymes
Aims: Olanzapine, a second-generation antipsychotic, can cause dose-adverse drug reactions. Its steady-state concentration can vary due to several factors. This study explores how physiological factors, smoking, inflammation, concomitant medications, and metabolic enzyme single nucleotide polymorphisms (SNPs) influence its metabolic levels, aiming to guide personalized dosing. Methods: This study analyzed data from 310 olanzapine-treated patients at Beijing Anding Hospital. Liquid chromatography-mass spectrometry (LC-MS/MS) quantified 1002 serum concentrations. Eleven SNPs from CYP1A2, CYP3A5, UGT1A4, and FMO1/3 were identified through real-time fluorescence quantitative polymerase chain reaction (q-PCR). A Bayesian network was applied to elucidate causal relationships between variables, followed by g-computation to quantify the effect of individual factors on the dose-adjusted concentration (C/D ratio) of olanzapine. The Wilcoxon signed-rank test assessed the intra-individual variations in the steady-state C/D ratio. Results: The Bayesian network suggested causality between smoking, sex, sertraline, Danggui-Longhui, valproic acid, and the olanzapine C/D ratio. None of the SNPs reached significance levels. The Wilcoxon signed-rank test confirmed that both polypharmacy and inflammation increased the C/D ratio within individuals. G-computation showed that the log ratio of olanzapine C/D decreased by 0.392 ± 0.037 in males and 0.004 ± 0.001 with smoking. Danggui-Longhui, sertraline, and valproic acid reduced the ratio by 0.652 ± 0.131, 0.398 ± 0.127, and 0.328 ± 0.039, respectively. Conclusion: Our study confirms that sex, age, smoking, inflammation, and co-prescription with sertraline, Danggui-Longhui, and valproic acid contributed to variability in olanzapine’s steady-state concentration. Considering these factors in clinical practice may help to personalize olanzapine treatment in Asian patients.
- 2 December 2024
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 34 (7) , 2083-2091
Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data
Pharmacovigilance findings have marked clozapine use. Prescribers and package inserts worldwide focus on clozapine-induced neutropenia. The literature on clozapine adverse drug reactions (ADRs) for those under age 18 and their associated fatal outcomes is limited. Reports to the World Health Organization’s global pharmacovigilance database (VigiBase) were analyzed among patients under 18 years of age extending from clozapine’s introduction to June 1, 2022. There were 2825 reports of clozapine, including 42 fatal outcomes (relative lethality = 1.5% vs. 11.7% in all ages). After 280 cases were excluded (clozapine exposure during pregnancy, accidental exposure or unclear age), 2455 were included with ADRs during therapeutic use. Decreased white blood cell (WBC) count provided the most frequent aggregated ADR, accounting for 934 cases (37% of 2545), with only 1 fatal outcome (0.01%, 1/934). Suicide explained 7 of 27 (26%) non-duplicated fatal outcomes. Next in importance was clozapine-induced gastrointestinal hypomotility (CIGH) with 3 cases (11% of 27) and neuroleptic malignant syndrome with 2 cases (7% of 27). Agranulocytosis, aspiration, myocarditis, myocardiopathy and ventricular arrythmia led to single fatal cases. Based on these new findings and recent literature in all ages, to prevent fatal outcomes, child and adolescent psychiatrists need to shift their focus from severe neutropenia to other ADRs including pneumonia, respiratory aspiration and CIGH. In spite of its potential toxicity during overdoses, clozapine may have specific and strong anti-suicidal effects when compared with other antipsychotics. Child and adolescent psychiatrists need to take extreme precautions to avoid intentional overdoses when prescribing clozapine to patients with suicide risk.
- 2 December 2024
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 34 (7) , 2083-2091
Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data
Pharmacovigilance findings have marked clozapine use. Prescribers and package inserts worldwide focus on clozapine-induced neutropenia. The literature on clozapine adverse drug reactions (ADRs) for those under age 18 and their associated fatal outcomes is limited. Reports to the World Health Organization’s global pharmacovigilance database (VigiBase) were analyzed among patients under 18 years of age extending from clozapine’s introduction to June 1, 2022. There were 2825 reports of clozapine, including 42 fatal outcomes (relative lethality = 1.5% vs. 11.7% in all ages). After 280 cases were excluded (clozapine exposure during pregnancy, accidental exposure or unclear age), 2455 were included with ADRs during therapeutic use. Decreased white blood cell (WBC) count provided the most frequent aggregated ADR, accounting for 934 cases (37% of 2545), with only 1 fatal outcome (0.01%, 1/934). Suicide explained 7 of 27 (26%) non-duplicated fatal outcomes. Next in importance was clozapine-induced gastrointestinal hypomotility (CIGH) with 3 cases (11% of 27) and neuroleptic malignant syndrome with 2 cases (7% of 27). Agranulocytosis, aspiration, myocarditis, myocardiopathy and ventricular arrythmia led to single fatal cases. Based on these new findings and recent literature in all ages, to prevent fatal outcomes, child and adolescent psychiatrists need to shift their focus from severe neutropenia to other ADRs including pneumonia, respiratory aspiration and CIGH. In spite of its potential toxicity during overdoses, clozapine may have specific and strong anti-suicidal effects when compared with other antipsychotics. Child and adolescent psychiatrists need to take extreme precautions to avoid intentional overdoses when prescribing clozapine to patients with suicide risk.
- 23 July 2024
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 20 (8) , 827-840
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders
To develop and validate a population pharmacokinetic (PPK) model of oral olanzapine in pediatric Chinese patients in order to individualize therapy in this population. A total of 897 serum concentrations from 269 pediatric patients taking oral olanzapine (ages 8 to 17 years) were collected. Demographic parameters, biological characteristics and concomitant medications were investigated as covariates. The data was analyzed using a nonlinear mixed-effects modeling approach. Bootstrapping (1000 runs), normalized prediction distribution error (NPDE), and external validation of 62 patients were employed. Simulations were performed to explore the individualized dosing regimens in various situations. The one-compartment model with first-order absorption and elimination had an apparent clearance (CL/F) of 10.38 L/h, a distribution volume (V/F) of 9.41 L/kg and an absorption rate constant (Ka) fixed at 0.3 h-1. The equation was CL∕F (L∕h) = 10.38 × (body weight∕60)0.25 ×1.33 (if male) × 0.71 (if co-occurrence of infection) × 0.51 (if co-therapy with fluvoxamine) × 1.27 (if co-therapy with sertraline) × 1.43 (if co-therapy with valproate). The final model had satisfactory stability, robustness, and predictive ability. The results from a simulation suggested the oral olanzapine doses required for male and female pediatric patients weighing between 40-60 kg without co-medication were 10-15 mg/day and 7.5-10 mg/day, respectively, and dosage adjustments should be based on sex and body weight; and co-administrated with valproate, sertraline, or fluvoxamine. This model may help individualize optimum dosing of oral olanzapine for pediatric patients.
- 23 July 2024
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 20 (8) , 827-840
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders
To develop and validate a population pharmacokinetic (PPK) model of oral olanzapine in pediatric Chinese patients in order to individualize therapy in this population. A total of 897 serum concentrations from 269 pediatric patients taking oral olanzapine (ages 8 to 17 years) were collected. Demographic parameters, biological characteristics and concomitant medications were investigated as covariates. The data was analyzed using a nonlinear mixed-effects modeling approach. Bootstrapping (1000 runs), normalized prediction distribution error (NPDE), and external validation of 62 patients were employed. Simulations were performed to explore the individualized dosing regimens in various situations. The one-compartment model with first-order absorption and elimination had an apparent clearance (CL/F) of 10.38 L/h, a distribution volume (V/F) of 9.41 L/kg and an absorption rate constant (Ka) fixed at 0.3 h-1. The equation was CL∕F (L∕h) = 10.38 × (body weight∕60)0.25 ×1.33 (if male) × 0.71 (if co-occurrence of infection) × 0.51 (if co-therapy with fluvoxamine) × 1.27 (if co-therapy with sertraline) × 1.43 (if co-therapy with valproate). The final model had satisfactory stability, robustness, and predictive ability. The results from a simulation suggested the oral olanzapine doses required for male and female pediatric patients weighing between 40-60 kg without co-medication were 10-15 mg/day and 7.5-10 mg/day, respectively, and dosage adjustments should be based on sex and body weight; and co-administrated with valproate, sertraline, or fluvoxamine. This model may help individualize optimum dosing of oral olanzapine for pediatric patients.
- Open Access
- 2 July 2024
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 20 (8) , 857-871
Investigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia
The literature associates clozapine with pneumonia/aspiration pneumonia. The international pharmacovigilance database (VigiBase™) uses the information component (IC) as statistical signal. VigiBase clozapine reports were analyzed for pneumonia/aspiration pneumonia from introduction to 10 May 2023. There were 6392 cases of all types of pneumonia (5572 cases of pneumonia, 775 of aspiration pneumonia, and 45 combined). The IC was 3.52 for aspiration pneumonia, introduced as a VigiBase label in 2003, and 1.91 for pneumonia. Patients were reclassified as 3628 with no signs of aspiration and 1533 with signs. Signs of aspiration were strongly associated with some co-medications: olanzapine, odds ratio (OR) = 23.8, 95% confidence interval (CI), 14.9-38.0; risperidone OR = 18.6, CI, 11.4-30.4; valproic acid, OR = 5.5, CI, 4.5-6.6; and benzodiazepines OR = 5.5, CI, 4.5-6.6. In 2415 cases with completed data, fatal outcomes made up 45% (signs of aspiration made no difference), but there was wide variability from 0% (females 64 years of age; duration >1 year). During the first week, pneumonia was associated with: 1) very high titration doses, 2) very small doses in Parkinson's disease and 3) Japan vs other countries. In clozapine-treated patients: 1) at least 30% of pneumonia cases may be aspiration pneumonia, 2) stopping some co-medications may decrease the risk of aspiration pneumonia, 3) average lethality in pneumonia was 45% but may be around 75% in geriatric patients in long-term treatment, and 4) safer titrations may sometimes require 5-mg tablets.
- 2 July 2024
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 20 (8) , 857-871
Open AccessInvestigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia
The literature associates clozapine with pneumonia/aspiration pneumonia. The international pharmacovigilance database (VigiBase™) uses the information component (IC) as statistical signal. VigiBase clozapine reports were analyzed for pneumonia/aspiration pneumonia from introduction to 10 May 2023. There were 6392 cases of all types of pneumonia (5572 cases of pneumonia, 775 of aspiration pneumonia, and 45 combined). The IC was 3.52 for aspiration pneumonia, introduced as a VigiBase label in 2003, and 1.91 for pneumonia. Patients were reclassified as 3628 with no signs of aspiration and 1533 with signs. Signs of aspiration were strongly associated with some co-medications: olanzapine, odds ratio (OR) = 23.8, 95% confidence interval (CI), 14.9-38.0; risperidone OR = 18.6, CI, 11.4-30.4; valproic acid, OR = 5.5, CI, 4.5-6.6; and benzodiazepines OR = 5.5, CI, 4.5-6.6. In 2415 cases with completed data, fatal outcomes made up 45% (signs of aspiration made no difference), but there was wide variability from 0% (females 64 years of age; duration >1 year). During the first week, pneumonia was associated with: 1) very high titration doses, 2) very small doses in Parkinson's disease and 3) Japan vs other countries. In clozapine-treated patients: 1) at least 30% of pneumonia cases may be aspiration pneumonia, 2) stopping some co-medications may decrease the risk of aspiration pneumonia, 3) average lethality in pneumonia was 45% but may be around 75% in geriatric patients in long-term treatment, and 4) safer titrations may sometimes require 5-mg tablets.
- 27 September 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 308-311
A Chinese medicine called Danggui Longhui may be a new clinically relevant clozapine inducer: Two case reports identified by therapeutic drug monitoring
- 27 September 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 308-311
A Chinese medicine called Danggui Longhui may be a new clinically relevant clozapine inducer: Two case reports identified by therapeutic drug monitoring
- 22 July 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 293-301
Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients
- 22 July 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 293-301
Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients
- 24 May 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 25-28
A brief history of clozapine in China with a look forward
- 24 May 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 25-28
A brief history of clozapine in China with a look forward